Merck has completed its acquisition of CN201, a bispecific antibody from Curon Biopharmaceutical, aimed at treating relapsed or refractory non-Hodgkin lymphoma and B-cell acute lymphocytic leukemia.
Merck & Co. has acquired Curon Biopharmaceutical's CN201, a CD3xCD19 bispecific T-cell engager, for up to $1.3 billion, strengthening its oncology pipeline.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.